Search Results - "Žácková, Daniela" :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia

The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia

by Pfirrmann, Markus, Clark, Richard E., Prejzner, Witold, Lauseker, Michael, Baccarani, Michele, Saussele, Susanne, Guilhot, François, Heibl, Sonja, Hehlmann, Rüdiger, Faber, Edgar, Turkina, Anna, Ossenkoppele, Gert, Höglund, Martin, Zaritskey, Andrey, Griskevicius, Laimonas, Olsson-Strömberg, Ulla, Everaus, Hele, Koskenvesa, Perttu, Labar, Boris, Sacha, Tomasz, Zackova, Daniela, Cervantes, Francisco, Colita, Adriana, Zupan, Irena, Bogdanovic, Andrija, Castagnetti, Fausto, Guilhot, Joëlle, Hasford, Joerg, Hochhaus, Andreas, Hoffmann, Verena S.
Published in Leukemia (01.08.2020)

Get full text

Journal Article

Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission

Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission

by Machova Polakova, Katerina, Zizkova, Hana, Zuna, Jan, Motlova, Eliska, Hovorkova, Lenka, Gottschalk, Andrea, Glauche, Ingmar, Koblihova, Jitka, Pecherkova, Pavla, Klamova, Hana, Stastna Markova, Marketa, Srbova, Dana, Benesova, Adela, Polivkova, Vaclava, Jurcek, Tomas, Zackova, Daniela, Mayer, Jiri, Ernst, Thomas, Mahon, Francois X., Saussele, Susanne, Roeder, Ingo, Cross, Nicholas C. P., Hochhaus, Andreas
Published in Leukemia (01.08.2020)

Get full text

Journal Article

Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF

Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF

by Žáčková, Daniela, Semerád, Lukáš, Faber, Edgar, Klamová, Hana, Stejskal, Lukáš, Bělohlávková, Petra, Karas, Michal, Cmunt, Eduard, Černá, Olga, Procházková, Jiřina, Čičátková, Petra, Kvetková, Anežka, Horňák, Tomáš, Skoumalová, Ivana, Srbová, Dana, Šálek, Cyril, Buffa, David, Voglová, Jaroslava, Jurček, Tomáš, Folta, Adam, Ježíšková, Ivana, Žižková, Hana, Machová Poláková, Kateřina, Papajík, Tomáš, Žák, Pavel, Jindra, Pavel, Svobodník, Adam, Štěpánová, Radka, Mayer, Jiří
Published in Leukemia (01.04.2024)

Get full text

Journal Article

Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR—final report from AFTER-SKI

Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR—final report from AFTER-SKI

by Richter, Johan, Lübking, Anna, Söderlund, Stina, Lotfi, Kourosh, Markevärn, Berit, Själander, Anders, Stenke, Leif, Deneberg, Stefan, Ahlstrand, Erik, Myhr-Eriksson, Kristina, Panayiotidis, Panayiotis, Gedde-Dahl, Tobias, Žáčková, Daniela, Mayer, Jiří, Olsson-Strömberg, Ulla, Mahon, Francois-Xavier, Saussele, Susanne, Hjorth-Hansen, Henrik, Koskenvesa, Perttu
Published in Leukemia (01.08.2021)

Get full text

Journal Article

Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia

Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia

by Racil, Zdenek, Razga, Filip, Drapalova, Jana, Buresova, Lucie, Zackova, Daniela, Palackova, Martina, Semerad, Lukas, Malaskova, Ludmila, Haluzik, Martin, Mayer, Jiri
Published in Haematologica (Roma) (01.10.2013)

Get full text

Journal Article

Clinical efficacy and safety of first‐line nilotinib or imatinib therapy in patients with chronic myeloid leukemia—Nationwide real life data

Clinical efficacy and safety of first‐line nilotinib or imatinib therapy in patients with chronic myeloid leukemia—Nationwide real life data

by Belohlavkova, Petra, Zackova, Daniela, Klamova, Hana, Faber, Edgar, Karas, Michal, Stejskal, Lukas, Cmunt, Eduard, Cerna, Olga, Jeziskova, Ivana, Machova Polakova, Katerina, Zak, Pavel, Jurkova, Tereza, Chrapava, Marika, Mayer, Jiri
Published in Cancer medicine (Malden, MA) (01.09.2024)

Get full text

Journal Article

Analysis of serum lipids, cardiovascular risk, and indication for statin use during nilotinib and imatinib therapy in de novo CML patients - results from real-life prospective study

Analysis of serum lipids, cardiovascular risk, and indication for statin use during nilotinib and imatinib therapy in de novo CML patients - results from real-life prospective study

by Horňák, Tomáš, Semerád, Lukáš, Žáčková, Daniela, Weinbergerová, Barbora, Šustková, Zuzana, Procházková, Jiřina, Bělohlávková, Petra, Stejskal, Lukáš, Rohoň, Peter, Faber, Edgar, Žák, Pavel, Mayer, Jiří, Ráčil, Zdeněk
Published in Leukemia & lymphoma (28.01.2020)

Get full text

Journal Article

Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy

Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy

by Racil, Zdenek, Koritakova, Eva, Sacha, Tomasz, Klamova, Hana, Belohlavkova, Petra, Faber, Edgar, Rea, Delphine, Malaskova, Ludmila, Prochazkova, Jirina, Zackova, Daniela, Voglova, Jaroslava, Wącław, Joanna, Cetkovsky, Petr, Zak, Pavel, Mayer, Jiri
Published in American journal of hematology (01.10.2018)

Get full text

Journal Article

Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia: patient-subgroups, prognostic impact, and technical aspects

Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia: patient-subgroups, prognostic impact, and technical aspects

by Culen, Martin, Borsky, Marek, Nemethova, Veronika, Razga, Filip, Smejkal, Jiri, Jurcek, Tomas, Dvorakova, Dana, Zackova, Daniela, Weinbergerova, Barbora, Semerad, Lukas, Sadovnik, Irina, Eisenwort, Gregor, Herrmann, Harald, Valent, Peter, Mayer, Jiri, Racil, Zdenek
Published in Oncotarget (31.05.2016)

Get full text

Journal Article

The significance of enzyme and transporter polymorphisms for imatinib plasma levels and achieving an optimal response in chronic myeloid leukemia patients

The significance of enzyme and transporter polymorphisms for imatinib plasma levels and achieving an optimal response in chronic myeloid leukemia patients

by Belohlavkova, Petra, Vrbacky, Filip, Voglova, Jaroslava, Racil, Zdenek, Zackova, Daniela, Hrochova, Katerina, Malakova, Jana, Mayer, Jiri, Zak, Pavel
Published in Archives of medical science (01.10.2018)

Get full text

Journal Article

Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes

Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes

by Perusini, Maria Agustina, Žáčková, Daniela, Kim, Taehyung, Pagnano, Katia, Pavlovsky, Carolina, Ježíšková, Ivana, Kvetková, Anežka, Jurček, Tomáš, Kim, Jaeyoon, Yoo, Youngseok, Yi, Seongyoon, Lee, Hyewon, Kim, Kyoung Ha, Chang, Myunghee, Capo-Chichi, Jose-Mario, Medeiros, Jessie J. F., Arruda, Andrea, Minden, Mark, Zhang, Zhaolei, Abelson, Sagi, Mayer, Jiri, Hwan Kim, Dennis Dong
Published in Blood advances (28.05.2024)

Get full text

Journal Article

Treatment Patterns in Patients with Chronic Myeloid Leukemia in Chronic Phase in the Third Line of TKI Therapy and Beyond Based on Real-World Evidence

Treatment Patterns in Patients with Chronic Myeloid Leukemia in Chronic Phase in the Third Line of TKI Therapy and Beyond Based on Real-World Evidence

by Dahlen, Torsten, Kockerols, Camille, Ferreira, Germano, Westerweel, Peter E., Mayer, Jiří, Sahmoud, Tarek, Wormser, David, Yau, Lillian, Žácková, Daniela
Published in Blood (23.11.2021)

Get full text

Journal Article

Estimation of current cumulative incidence of leukaemia-free patients and current leukaemia-free survival in chronic myeloid leukaemia in the era of modern pharmacotherapy

Estimation of current cumulative incidence of leukaemia-free patients and current leukaemia-free survival in chronic myeloid leukaemia in the era of modern pharmacotherapy

by Pavlík, Tomáš, Janoušová, Eva, Pospíšil, Zdeněk, Mužík, Jan, Záčková, Daniela, Ráčil, Zdeněk, Klamová, Hana, Cetkovský, Petr, Trněný, Marek, Mayer, Jiří, Dušek, Ladislav
Published in BMC medical research methodology (11.10.2011)

Get full text

Journal Article

P669: ANALYSIS OF FACTORS INFLUENCING THE DECISION TO STOP TKI TREATMENT IN CML PATIENTS IN DEEP MOLECULAR RESPONSE

P669: ANALYSIS OF FACTORS INFLUENCING THE DECISION TO STOP TKI TREATMENT IN CML PATIENTS IN DEEP MOLECULAR RESPONSE

by Semerad, Lukas, Žáčková, Daniela, Belohlavkova, Petra, Voglova, Jaroslava, Žák, Pavel, Faber, Edgar, Papajik, Tomas, Skoumalova, Ivana, Karas, Michal, Jindra, Pavel, Klamová, Hana, Salek, Cyril, Srbová, Dana, Zizkova, Hana, Stejskal, Lukas, Cerna, Olga, Cmunt, Eduard, Cicatkova, Petra, Kvetkova, Anezka, Hornak, Tomas, Jeziskova, Ivana, Jurcek, Tomas, Weinbergerová, Barbora, Prochazkova, Jirina, Machova Polakova, Katerina, Svobodnik, Adam, Stepanova, Radka, Mayer, Jiri
Published in HemaSphere (08.08.2023)

Get full text

Journal Article

Somatic Mutations in Myeloid Transcription Factors and in Activated Signaling Pathway, but Not in Epigenetic Modifier Pathway, Predict the Risk of Treatment Failure and Progression to Advanced Phase in Chronic Myeloid Leukemia

Somatic Mutations in Myeloid Transcription Factors and in Activated Signaling Pathway, but Not in Epigenetic Modifier Pathway, Predict the Risk of Treatment Failure and Progression to Advanced Phase in Chronic Myeloid Leukemia

by Kim, Taehyung, Žácková, Daniela, Ježíšková, Ivana, Kvetková, Anežka, Jurček, Tomáš, Yoo, Young Seok, Lee, Hyewon, Kim, Kyoung Ha, Chang, Myung Hee, Yi, Seong Yoon, Medeiros, Jessie J.F., Abelson, Sagi, Kim, Dennis
Published in Blood (15.11.2022)

Get full text

Journal Article

A Risk Model for CML Patients with COVID-19: Importance of Molecular Response in the Context of Age, Comorbidities and Country Income

A Risk Model for CML Patients with COVID-19: Importance of Molecular Response in the Context of Age, Comorbidities and Country Income

by Radich, Jerald P., Kok, Chung Hoow, Chelysheva, Ekaterina Yu, Cortes, Jorge E., Jiang, Qian, Mauro, Michael, Milojkovic, Dragana, Moiraghi, Beatriz, Nicolini, Franck E., Ongondi, Matilda, Pagnano, Katia B, Žácková, Daniela, Rea, Delphine, Evans, Nicola, Hughes, Timothy
Published in Blood (15.11.2022)

Get full text

Journal Article

Constant BCR-ABL transcript level ≥0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis

Constant BCR-ABL transcript level ≥0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis

by Poláková, Kateřina Machová, Polívková, Václava, Rulcová, Jana, Klamová, Hana, Jurček, Tomáš, Dvořáková, Dana, Žáčková, Daniela, Pospíšil, Zdeněk, Mayer, Jiří, Moravcová, Jana
Published in Experimental hematology (2010)

Get full text

Journal Article

The Prognostic Impact of HMGCLL1 Gene Variant on Treatment Outcomes in Chronic Myeloid Leukemia (CML) Patients: Adverse Impact on the Response, Failure, and Progression with Imatinib Which Can be Abrogated By the Use of 2nd Generation Tyrosine Kinase Inhibitor (TKI) Upfront Therapy

The Prognostic Impact of HMGCLL1 Gene Variant on Treatment Outcomes in Chronic Myeloid Leukemia (CML) Patients: Adverse Impact on the Response, Failure, and Progression with Imatinib Which Can be Abrogated By the Use of 2nd Generation Tyrosine Kinase Inhibitor (TKI) Upfront Therapy

by Perusini, Maria Agustina, Kim, Taehyung Simon, Žácková, Daniela, Pagnano, Katia B, Mayer, Jiří, Pavlovsky, Carolina, Ježíšková, Ivana, Kvetková, Anežka, Jurček, Tomáš, Moiraghi, Beatriz, Varela, Ana Ines, Bianchini, Michele, Lopes, Ana Beatriz Pascoal, Duarte, Gislaine B O, Yoo, Young Seok, Souza, Carmino Antonio, Medeiros, Jessie, Lee, Hye Won, Kim, Kyoung Ha, Yi, Seong Yoon, Chang, Myung Hee, Abelson, Sagi, Kim, Dennis Dong Hwan
Published in Blood (15.11.2022)

Get full text

Journal Article

Effectiveness of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after Two or More Prior Tyrosine Kinase Inhibitors

Effectiveness of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after Two or More Prior Tyrosine Kinase Inhibitors

by Dahlén, Torsten, Kockerols, Camille C.B., Ferreira, Germano, Westerweel, Peter E., Mayer, Jiri, Allepuz, Alex, Wormser, David, Yau, Lillian, Žácková, Daniela
Published in BLOOD (15.11.2022)

Get full text

Journal Article Conference Proceeding

Somatic Mutations Are Frequently Detected in CML Patients before Treatment-Free Remission (TFR) Attempt with Tyrosine Kinase Inhibitor (TKI) Discontinuation but with Uncertain Predictive Value for Tfr Failure

Somatic Mutations Are Frequently Detected in CML Patients before Treatment-Free Remission (TFR) Attempt with Tyrosine Kinase Inhibitor (TKI) Discontinuation but with Uncertain Predictive Value for Tfr Failure

by Perusini, Maria Agustina, Pagnano, Katia B, Pavlovsky, Carolina, Moiraghi, Beatriz, Varela, Ana Ines, Bianchini, Michele, Mayer, Jiří, Žácková, Daniela, Kvetková, Anežka, Jurček, Tomáš, Ježíšková, Ivana, Lopes, Ana Beatriz Pascoal, Duarte, Gislaine B O, Souza, Carmino Antonio, Medeiros, Jessie J.F., Kim, Taehyung Simon, Yoo, Young Seok, Kim, Kyoung Ha, Lee, Hye Won, Chang, Myung Hee, Yi, Seong Yoon, Abelson, Sagi, Kim, Dennis
Published in Blood (15.11.2022)

Get full text

Journal Article